Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:INVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$234.48+0.7%$195.53$96.09▼$238.56$11.98B0.59762,044 shs913,855 shsINVAInnoviva$21.42-2.1%$22.90$16.52▼$25.15$1.58B0.38747,111 shs1.16 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.71%-0.63%+27.47%+43.07%+127.67%INVAInnoviva-2.15%-4.63%-7.07%-6.71%+12.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$234.48+0.7%$195.53$96.09▼$238.56$11.98B0.59762,044 shs913,855 shsINVAInnoviva$21.42-2.1%$22.90$16.52▼$25.15$1.58B0.38747,111 shs1.16 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.71%-0.63%+27.47%+43.07%+127.67%INVAInnoviva-2.15%-4.63%-7.07%-6.71%+12.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 2.90Moderate Buy$251.267.16% UpsideINVAInnoviva 2.57Moderate Buy$36.2069.00% UpsideCurrent Analyst Ratings BreakdownLatest AXSM and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.005/5/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$217.00 ➝ $242.005/5/2026AXSMAxsome Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$228.00 ➝ $310.005/5/2026AXSMAxsome Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$241.00 ➝ $246.005/4/2026AXSMAxsome Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$708.24M17.04N/AN/A$1.06 per share221.21INVAInnoviva$420.69M3.76$4.92 per share4.35$18.18 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$183.17M-$3.73N/A58.18N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)INVAInnoviva$271.17M$6.013.568.57N/A119.89%33.33%22.67%8/5/2026 (Estimated)Latest AXSM and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics2.271.391.32INVAInnoviva0.1921.1320.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%INVAInnoviva99.12%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics20.60%INVAInnoviva2.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableAXSM and INVA HeadlinesRecent News About These CompaniesInnoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More1 hour ago | theglobeandmail.comTheravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19May 27 at 8:50 PM | tipranks.comIs Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?May 11, 2026 | finance.yahoo.comInnoviva (NASDAQ:INVA) Stock Rating Lowered by Wall Street ZenMay 9, 2026 | marketbeat.comInnoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty StrengthMay 8, 2026 | insidermonkey.comTheravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price TargetMay 7, 2026 | tipranks.comBTIG Research Issues Positive Forecast for Innoviva (NASDAQ:INVA) Stock PriceMay 7, 2026 | marketbeat.comInnoviva (NASDAQ:INVA) Releases Earnings Results, Beats Estimates By $1.79 EPSMay 6, 2026 | marketbeat.comInnoviva (INVA) Tops Q1 Earnings EstimatesMay 6, 2026 | zacks.comInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressMay 6, 2026 | businesswire.comJennison Associates LLC Buys New Shares in Innoviva, Inc. $INVAMay 4, 2026 | marketbeat.comHussman Strategic Advisors Inc. Boosts Stock Position in Innoviva, Inc. $INVAMay 3, 2026 | marketbeat.comInnoviva, Inc. (INVA) Stock Price, News, Quote & History - Yahoo FinanceApril 30, 2026 | finance.yahoo.comMerck (MRK) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2026 | zacks.comUniversal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Innoviva, Inc. $INVAApril 30, 2026 | marketbeat.com3 Bargain-Cheap Small Caps Worth a Second Look (INVA)...April 9, 2026 | marketbeat.comAnalysts see this pharma stock surging 60%; eyes fresh entryApril 2, 2026 | msn.comTheravance Secures Long-Term YUPELRI Patent Litigation SettlementMarch 30, 2026 | tipranks.comIs It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price GainsMarch 24, 2026 | finance.yahoo.comTheravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral StanceMarch 22, 2026 | tipranks.comIs Innoviva (NASDAQ:INVA) Entering A Stronger Phase In Nasdaq Composite?March 20, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM and INVA Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$234.48 +1.65 (+0.71%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$233.92 -0.56 (-0.24%) As of 05/29/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Innoviva NASDAQ:INVA$21.42 -0.47 (-2.15%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$21.41 -0.01 (-0.05%) As of 05/29/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
